01What we do
One hyperlean, AI-native platform. Built, proven, now expanding.
We in-license and co-develop, then carry each molecule through registration, access and launch, at a fraction of the usual cost and time.
-
What we take on
Three asset classes
Biologics, biosimilars and complex generics where the need is real and the path to launch is credible.
-
How we do it
In-licensing and co-dev
Partners manufacture; we own registration, access and launch.
-
Why we are fast
AI-native, end-to-end
One platform runs screening, submissions and launch readiness, in parallel, not in sequence.
02Saya speed
4–5 months from program decision to submission.
~4×Asset-to-market pace vs industry
One teamRuns every signed molecule
03Progress to date · Mexico
Proof that the model works.
- Signed molecules
- 13
- Regulatory submissions
- 11
- COFEPRIS approvals secured
- 4
- In biologics submissions, Mexico 2025
- #1
- International partnerships
- 8
- Formation to first launch
- 4 yrs
Selling in market todayFirst sale completed. Mexico is our first proof of execution, not a pilot.
Next milestone
First US anchor asset announced before the end of 2026. First sale in the Central American market in 2027.
04Our partners
International partners already build with us.
05Pipeline
13 signed molecules across four therapeutic areas.
- 4In commercialisation
- 7Submitted to COFEPRIS
- 2Signed
Rheumatology & bone
- TeriparatideIn market
- Hyaluronic acid 1%In market
- Hyaluronic acid 1.5%In market
- Hyaluronic acid 2%In market
- Denosumab 60 mgSubmitted
Oncology & supportive care
- BevacizumabSubmitted
- PegfilgrastimSubmitted
- Denosumab 120 mgSubmitted
Cardio-metabolic
- LiraglutideSubmitted
- Sitagliptin / metforminSubmitted
- Metformin XRSigned
- Rosuvastatin / ezetimibeSigned
Immunology
- Mycophenolic acidSubmitted
+5 / yearOur goal is to add at least five new molecules to the pipeline every year.